{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-006932","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.902318+00:00","generated_at":"2026-06-26T01:03:01.804689+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Techne Q3 FY2022 revenue $290.4M (+17% organic), record adj. EPS $2.14","bullets":["Q3 organic revenue +17% to $290.4M (reported +19%); YTD organic +18% to $817.4M.","Record adjusted EPS $2.14 (GAAP EPS $1.48) vs $1.80 prior year.","Protein Sciences organic +16%; Diagnostics & Genomics organic +19%.","Declared quarterly dividend $0.32/share, payable May 27 to holders of record May 16.","Announced exclusive agreement with Thermo Fisher to commercialize ExoTRU kidney transplant test."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-006932","json":"https://secwatch.observer/filing/0001558370-22-006932.json","markdown":"https://secwatch.observer/filing/0001558370-22-006932.md","text":"https://secwatch.observer/filing/0001558370-22-006932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000155837022006932/0001558370-22-006932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000155837022006932/tmb-20220504x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:03:01.804689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}